AbbVie Reveals Promising Phase 3 TEMPO-1 Trial Results for Tavapadon as a Solo Parkinson’s Therapy.

Merck to Showcase Extended Data on Tulisokibart (MK-7240), a Trial Anti-TL1A Monoclonal Antibody, in IBD at UEG Week 2024.

Capstan Therapeutics will showcase preclinical findings on their lead in vivo CAR-T candidate, CPTX2309, at the 2024 ACR Convergence.

Enanta Pharmaceuticals Reveals Encouraging Phase 2a Results for EDP-323 in Healthy Adults Challenged with RSV.

enGene Holdings Advances in Clinical-Stage Genetic Medicine with Key Study on Non-Viral Therapy for High-Risk Bladder Cancer.

Sage Therapeutics, Inc. (NASDAQ: Sage) disclosed that Biogen has relinquished its rights under the collaboration and license deal with Sage concerning the SAGE-324 program.

LEO Pharma Unveils New Phase 2a Trial Findings for Temtokibart and Dupilumab in Moderate-to-Severe Atopic Dermatitis at 2024 EADV Annual Conference.

ReCode Therapeutics Administers Initial Dose in Phase 1b Study of RCT2100 for Cystic Fibrosis Treatment.

AstraZeneca’s Tagrisso (osimertinib) has received approval in the United States for treating adult patients with unresectable Stage III EGFRm NSCLC.

The FDA has granted IND approval for the world's first liquid recombinant Botulinum Toxin Type A formulation.

Innovent Reports NMPA NDA Approval for Picankibart (Anti-IL-23p19 Antibody) in Moderate to Severe Plaque Psoriasis Treatment.

Pfizer Voluntarily Removes All Batches of Sickle Cell Disease Drug OXBRYTA® (voxelotor) From Global Market.